IL6 and metastatic neoplasm: In PC patients, IL-6 levels are higher in metastatic disease than in locally advanced tumors (p = 0.0001) [94] and IL-6 released by myeloid cells in TME activates STAT3 signaling in PC cells, hence affecting poor patient’s outcome [192].